Top Markets
#1 PulseChain PulseChain +45.01%
#2 SkyAI SkyAI +17.01%
#3 Orochi Network Orochi Network +10.19%
#4 Pump.fun Pump.fun +9.55%
#5 Unit Pump Unit Pump +9.55%
#6 eCash eCash +9.31%
#7 Fake World Assets Fake World Assets +8.82%
#8 OPENLOOT OPENLOOT +8.48%
#9 Meteora Meteora +8.22%
#10 Glidr Glidr +8.12%
Coin of the day
PulseChain PulseChain
Einstellungen
Sprache
DEUTSCH
Währung
USD
Thema
Codex DNA, Inc. Codex DNA, Inc.

Codex DNA, Inc.

DNAY
Rang in Aktien #28192
Operating in the synthetic biology sector, Codex DNA, Inc. develops,... Operating in the synthetic biology sector, Codex DNA, Inc. develops, manufactures, and sells advanced instruments, reagents, and complementary services. Its primary customer base comprises pharmaceutical firms and academic laboratories worldwide, though it also extends its offerings to government institutions, contract research organizations, and other synthetic biology companies. The company's innovative product portfolio includes the BioXp system, designed to transform digital DNA sequences into usable synthetic DNA, alongside the intuitive BioXp portal, an online platform facilitating DNA sequence design and assembly into chosen vectors. Researchers can also access BioXp kits, which supply essential building blocks and reagents, including the proprietary Gibson Assembly brand, for specific synthetic biology applications. Further support is provided through cloud-based scripts and specialized benchtop reagents for processing products generated by the BioXp system. Moreover, Codex DNA offers Biofoundry Services, allowing clients to commission and receive endpoint-ready BioXp products like genes, clones, cell-free amplified DNA, and variant libraries, in addition to providing short oligo ligation assembly enzymatic DNA synthesis. Established in 2011 and headquartered in San Diego, California, the company rebranded as Codex DNA, Inc. in March 2020, having previously been known as SGI-DNA, Inc.
Aktienkurs
$1.30
Zuletzt synchronisiert: 2023-01-03
Marktkapitalisierung
$27.96M
Veränderung (1 Tag)
8.33%
Veränderung (1 Jahr)
0.00%
Land
US
Handel Codex DNA, Inc. (DNAY)

Kategorie

Healthcare
Gewinn für Codex DNA, Inc. (DNAY)
Gewinn im 2026 TTM: 0
Laut den aktuellen Finanzberichten von Codex DNA, Inc. betragen die aktuellen Gewinne des Unternehmens 0. Im Jahr 2026 erzielte das Unternehmen einen Gewinn von 0, gleich wie dem Gewinn im Jahr 2026, der 0 betrug. Die auf dieser Seite angezeigten Gewinne sind die Gewinne vor Zinsen und Steuern, auch bekannt als EBIT.
Gewinnverlauf von Codex DNA, Inc. von 2026 bis 2026
Gewinn am Ende jedes Jahres
Jahr Gewinn ändert
Nicht genügend Daten für die angegebenen Daten.
Gewinn ähnlicher Unternehmen oder Konkurrenten
Unternehmen Gewinn Gewinnunterschied Land
Abbott Laboratories Abbott Laboratories
Abbott Laboratories
ABT.US
$7.51B -
US
Stryker Corporation Stryker Corporation
Stryker Corporation
SYK.US
$5.15B -
US
Medtronic plc Medtronic plc
Medtronic plc
MDT.US
$5.56B -
IE
Boston Scientific Corporation Boston Scientific Corporation
Boston Scientific Corporation
BSX.US
$3.86B -
US
Edwards Lifesciences Corporation Edwards Lifesciences Corporation
Edwards Lifesciences Corporation
EW.US
$1.42B -
US